PEriToneal Catheter Versus Repeated Paracentesis for Ascites in Cirrhosis
关键词
抽象
描述
Ten percent of patients with cirrhosis develop ascites. In 90% of patients, ascites can be treated with diuretics. The management of the remaining 10% with diuretic resistant ascites is challenging. Symptoms including abdominal pain, dyspnoea, nausea, vomiting, and anorexia have a detrimental impact on the quality of life. Repeated large volume paracentesis provides only temporary improvement of symptoms.
Insertion of a tunnelated peritoneal catheter (PleurX) allows repeated intermittent small volume fluid drainage at home. The treatment may improve the management of ascites and have a beneficial effect on the quality of life.
To evaluate the beneficial and harmful effects of the peritoneal catheter (PleurX) versus repeated large volume paracentesis for patients with cirrhosis and diuretic resistant ascites.
Investigator initiated, randomised, single blind, parallel arm, controlled trial.
Due to the nature of the intervention and the primary outcome measure, Investigators are unable to conduct the trial with blinding of the patients, the investigators or use blinded outcome assessment.
Tunnelated peritoneal (PleurX) catheter versus large volume paracentesis. All patients will receive ciprofloxacin to prevent spontaneous bacterial peritonitis.
The study investigators will include 32 adult patients with cirrhosis of any aetiology and diuretic resistant ascites.
Gastrounit, Hvidovre University Hospital, Department of Gastroenterology and Hepatology, Odense University Hospital, Department of Gastroenterology and Hepatology, Aarhus University Hospital, and Centre for Hepatology, UCL Institute for Liver and Digestive Health, Royal Free Campus, University College London, UK 18 months. The total duration of follow up is six months. The primary outcome is paracentesis free survival. Secondary outcomes include cumulative number of paracentesis, cirrhosis-related complications, safety, quality of life, changes in metabolic and nutritional parameters, circulatory dysfunction, renal function, cardiac output, neuro-humoral changes.
日期
| 最后验证: | 04/30/2019 |
| 首次提交: | 12/12/2016 |
| 提交的预估入学人数: | 01/19/2017 |
| 首次发布: | 01/22/2017 |
| 上次提交的更新: | 05/15/2019 |
| 最近更新发布: | 05/19/2019 |
| 实际学习开始日期: | 01/19/2017 |
| 预计主要完成日期: | 05/14/2019 |
| 预计完成日期: | 05/14/2019 |
状况或疾病
干预/治疗
Device: PleurX
Device: Large Volume Paracentesis
Drug: Ciprofloxacin 500Mg Tablet
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Experimental: PleurX The PleurX catheter is a tunnelated peritoneal catheter, designed for permanent placement in the peritoneal cavity. The catheter is placed by a physician under sterile conditions. Drainage of ascites is done using vacuum bottles connected to the catheter. This can be managed by a home nurse or the patient. | Device: PleurX A permanent catheter |
| Active Comparator: Large Volume Paracentesis Large volume paracentesis is performed in sterile technique, a small incision is made through the skin, and a catheter is inserted through muscle and peritoneum. After the procedure, the patient remains in hospital for observation until the fluid is drained. | Device: Large Volume Paracentesis Short time drainage |
资格标准
| 有资格学习的年龄 | 18 Years 至 18 Years |
| 有资格学习的性别 | All |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: - Cirrhosis of any aetiology - Diuretic resistant ascites defined as i) an inability to mobilise ascites (minimal or no weight loss) despite administration with the maximum tolerable doses of oral diuretics or a daily dose of spironolactone 400 mg and re-accumulation of fluid after therapeutic paracentesis within two weeks or ii) diuretic-related complications including (but not limited to) azotemia, hepatic encephalopathy, or progressive electrolyte imbalances - Able to read and understand Danish - Signed and dated informed consent form - Willing to comply with all study procedures and be available for the duration of the study - Male or female of any age - Age at least 18 years - Expected survival at least three months. Exclusion Criteria: - Participants eligible and listed for TIPS - Serum creatinine levels above 135 umol/L - Overt hepatic encephalopathy in the two weeks before randomization - Ascites due to other causes than cirrhosis such as: malignant disease, congestive heart failure, end-stage renal disease, pancreatitis, or Budd-Chiari (hepatic vein thrombosis), or chylous ascites - Ongoing intra-abdominal infection (peritonitis) or active systemic or local infections, such as urinary tract infection or pneumonia - Participation in a clinical study that may interfere with participation in this study; - Evidence of extensive ascites loculation - Coagulopathy - Variceal bleeding within two weeks before randomisation - Intraabdominal surgery within four months before randomisation - Spontaneous bacterial peritonitis (neutrophil count>250/µl within 24 hours of randomization) - Patients with an increased risk of procedure related complications as judged by the primary healthcare provider |
结果
主要结果指标
1. Time to first paracentesis [18 months]
次要成果指标
1. Adverse events [18 months]
2. Nutritional Status [18 months]
3. Renal function [18 months]
4. Cardiac Output [18 months]
